Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dose-escalation study of thoracic radiotherapy in combination with pemetrexed plus Cisplatin followed by pemetrexed consolidation therapy in Japanese patients with locally advanced nonsquamous non-small-cell lung cancer.
Niho S, Kubota K, Nihei K, Sekine I, Sumi M, Sekiguchi R, Funai J, Enatsu S, Ohe Y, Tamura T. Niho S, et al. Among authors: funai j. Clin Lung Cancer. 2013 Jan;14(1):62-9. doi: 10.1016/j.cllc.2012.03.007. Epub 2012 May 24. Clin Lung Cancer. 2013. PMID: 22633219 Clinical Trial.
Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan.
Okusaka T, Nakachi K, Fukutomi A, Mizuno N, Ohkawa S, Funakoshi A, Nagino M, Kondo S, Nagaoka S, Funai J, Koshiji M, Nambu Y, Furuse J, Miyazaki M, Nimura Y. Okusaka T, et al. Among authors: funai j. Br J Cancer. 2010 Aug 10;103(4):469-74. doi: 10.1038/sj.bjc.6605779. Epub 2010 Jul 13. Br J Cancer. 2010. PMID: 20628385 Free PMC article. Clinical Trial.
The efficacy and safety of gemcitabine plus paclitaxel combination first-line therapy for Japanese patients with metastatic breast cancer including triple-negative phenotype.
Aogi K, Yoshida M, Sagara Y, Kamigaki S, Okazaki M, Funai J, Fujimoto T, Toi M, Saeki T, Takashima S. Aogi K, et al. Among authors: funai j. Cancer Chemother Pharmacol. 2011 May;67(5):1007-15. doi: 10.1007/s00280-010-1390-1. Epub 2010 Jul 14. Cancer Chemother Pharmacol. 2011. PMID: 20628744 Clinical Trial.
A phase I study of tasisulam sodium using an albumin-tailored dose in Japanese patients with advanced solid tumors.
Fujiwara Y, Ando Y, Mukohara T, Kiyota N, Chayahara N, Mitsuma A, Inada-Inoue M, Sawaki M, Ilaria R Jr, Kellie Turner P, Funai J, Maeda K, Minami H. Fujiwara Y, et al. Among authors: funai j. Cancer Chemother Pharmacol. 2013 Apr;71(4):991-8. doi: 10.1007/s00280-013-2092-2. Epub 2013 Feb 1. Cancer Chemother Pharmacol. 2013. PMID: 23370664 Clinical Trial.
Incidence of diabetes mellitus and neoplasia in Japanese short-statured children treated with growth hormone in the Genetics and Neuroendocrinology of Short Stature International Study (GeNeSIS).
Yokoya S, Hasegawa T, Ozono K, Tanaka H, Kanzaki S, Tanaka T, Chihara K, Jia N, Child CJ, Ihara K, Funai J, Iwamoto N, Seino Y. Yokoya S, et al. Among authors: funai j. Clin Pediatr Endocrinol. 2017;26(4):229-241. doi: 10.1297/cpe.26.229. Epub 2017 Sep 28. Clin Pediatr Endocrinol. 2017. PMID: 29026272 Free PMC article.
Responses to the Letter to the Editor "Does growth-hormone treatment affect patients with and without a mitochondrial disorder differentially ?" (Vol. 27, No. 2, p. 107-108, 2018).
Yokoya S, Hasegawa T, Ozono K, Tanaka H, Kanzaki S, Tanaka T, Chihara K, Jia N, Child CJ, Ihara K, Funai J, Iwamoto N, Seino Y. Yokoya S, et al. Among authors: funai j. Clin Pediatr Endocrinol. 2018;27(3):201-202. doi: 10.1297/cpe.27.201. Epub 2018 Jul 31. Clin Pediatr Endocrinol. 2018. PMID: 30083039 Free PMC article. No abstract available.
18 results